 |
29 Products |  |
56 Diseases | | 29 Products |
|
157 Trials |  |
7389 News |  |
| 12345678910111213...9697» |
- || Cervidil (dinoprostone) / Ferring
Clinical, Journal: Comparison of perinatal outcomes using oral misoprostol, vaginal misoprostol, and intracervical dinoprostone for induction of labor. (Pubmed Central) - May 27, 2025
The disadvantage of this method is a significant increase in the time from the start of induction to the delivery of the fetus. There was no difference in the occurrence of severe perinatal complications between the induction methods.
- || quinagolide vaginal ring (FE-999051) / Ferring
Clinical, Journal: Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. (Pubmed Central) - May 21, 2025
P2
Our primary analysis showed no significant difference between treatment groups in terms of change in total lesion size. Many patients in this study presented with advanced disease, which may be less responsive to quinagolide than highly vascularized superficial lesions, as quinagolide inhibits the VEGF signaling pathway.
- | Cervidil (dinoprostone) / Ferring
Journal: Induction of labor in high-risk nulliparous women with unfavorable cervix. (Pubmed Central) - May 21, 2025
Dinoprostone first use resulted in a shorter time to delivery, with no maternal-fetal side effects. There is then no need to prolong IOL and raise maternal stress, as this will not yield better outcomes.
- | Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Journal: Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer, a study with 5-year follow-up: a plain language summary. (Pubmed Central) - May 21, 2025
There is then no need to prolong IOL and raise maternal stress, as this will not yield better outcomes. No abstract available
- || Entyvio (vedolizumab) / Takeda
Retrospective data, Review, Journal: Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-? in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis. (Pubmed Central) - May 20, 2025
Real-world use of vedolizumab was associated with favourable long-term effectiveness and treatment persistence. Vedolizumab is a suitable first-line biological option for biologic-naive patients with CD.
- | Journal, Real-world evidence, Real-world: Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment. (Pubmed Central) - May 20, 2025
Vedolizumab is a suitable first-line biological option for biologic-naive patients with CD. This study identifies paradoxical IBD as a consistent positive signal across multiple IMID agents, predominantly manifesting as CD, potentially aiding in timely detection and therapeutic decision-making.
- || Biomarker, Review, Journal: Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review. (Pubmed Central) - May 20, 2025
Our analysis spans multiple omics disciplines, including genomics, transcriptomics (both bulk RNA and single-cell RNA sequencing), proteomics, microbiomics, and metabolomics, with particular emphasis on the impact of models integrating multiple omics datasets. Additionally, to further the field of precision medicine, we evaluated specific biomarkers that may exhibit distinct effects on responses to multiple therapeutic interventions.
- || Cervidil (dinoprostone) / Ferring
Retrospective data, Review, Journal: Inpatient vaginal dinoprostone vs outpatient balloon catheters for cervical ripening in induction of labor: An individual participant data meta-analysis of randomized controlled trials. (Pubmed Central) - May 19, 2025
In pre-planned subgroup analysis, for pregnant women with underweight/normal weight, both inpatient vaginal dinoprostone and outpatient balloon catheter methods are viable options, but balloon catheter has a lower vaginal birth rate in women with overweight and obesity during pregnancy. The perinatal and maternal safety profiles are comparable.
- ||| Journal, Adverse events: Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry. (Pubmed Central) - May 19, 2025
The perinatal and maternal safety profiles are comparable. Our data support that, overall, the new biologic treatments have a superior safety profile in real-world practice compared to adalimumab and its biosimilars.
- || Firmagon (degarelix) / Astellas, Ferring
Retrospective data, Review, Journal: Risk of cardiovascular disease following degarelix versus gonadotropin-releasing hormone agonists in patients with prostate cancer: a systematic review and meta-analysis. (Pubmed Central) - May 18, 2025
Degarelix demonstrates a lower incidence of major adverse cardiovascular events compared to GnRH agonists, suggesting a potential cardiovascular safety advantage in prostate cancer treatment. Further studies are required to prove the results of our systematic review and meta-analysis.
- | Menopur (menotropin) / Ferring
Preclinical, Journal: Chemotherapy-induced diminished murine ovarian reserve model and impact of low-dose chemotherapy on fertility. (Pubmed Central) - May 17, 2025
We successfully established a chemotherapy-induced DOR model using 12 mg/kg of Bu + 120 mg/kg of Cy, as evidenced by lower, but not completely depleted, follicle numbers and fewer retrieved embryos. Histologic study of ovarian tissue exposed to DOR-inducing chemotherapy revealed that surviving follicles were of the similar quality as tissue not exposed to chemotherapy.
- | Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis. (Pubmed Central) - May 16, 2025
Histologic study of ovarian tissue exposed to DOR-inducing chemotherapy revealed that surviving follicles were of the similar quality as tissue not exposed to chemotherapy. CZP may be more effective than Fc?containing TNFi in patients with RA and high RF levels.
- || Firmagon (degarelix) / Astellas, Ferring
Retrospective data, Review, Journal: A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer. (Pubmed Central) - May 16, 2025
CZP may be more effective than Fc?containing TNFi in patients with RA and high RF levels. In patients with prostate cancer, degarelix is associated with a significantly lower incidence of major adverse cardiovascular events.
- | Pentasa enema (mesalazine rectal enema) / Ferring, Pentasa foam (mesalazine foam) / Ferring, Takeda
Journal: Diagnostic Challenges of Upper Gastrointestinal Tract Crohn's Disease. (Pubmed Central) - May 16, 2025
Despite multiple normal findings on various endoscopic and imaging evaluations, his symptoms persisted, leading to numerous treatment modifications from Pentasa foam enema to various biologics. This case underscores the diagnostic challenges of upper
- || Review, Journal: Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence. (Pubmed Central) - May 16, 2025
This case underscores the diagnostic challenges of upper This review analyses the
- | Cervidil (dinoprostone) / Ferring
Journal: Ultrasound-guided insertion of controlled-release dinoprostone vaginal delivery system (PROPESS). (Pubmed Central) - May 15, 2025
This review analyses the No abstract available
- ||| Retrospective data, Journal, Adverse events, Real-world evidence: Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study. (Pubmed Central) - May 15, 2025
Doctors need to pay close attention to the appearance of mycobacterial infectious disorders in older adults treating with TNF-? inhibitors, which displayed the strongest signal.
- | Cervidil (dinoprostone) / Ferring
Journal: Obstetric Use of Prostaglandin Preparations Compared to Mechanical Methods for Cervical Ripening in Pregnancies With Premature Rupture of Membranes at Term. (Pubmed Central) - May 14, 2025
Background We examined the difference in obstetric outcomes between the cases using dinoprostone and those using mechanical methods in pregnant women requiring cervical ripening following premature rupture of the membranes (PROMs) at term...The clinical intrauterine infection in the cases of the mechanical methods group occurred more than 2 days after the start of cervical ripening; however, there was no case of neonatal infection in the two groups. Conclusions There were differences in the characteristics of the effects between the two methods in pregnant women with PROM who have an unfavorable cervix; however, there were no differences in the final perinatal outcome.
- | Cervidil (dinoprostone) / Ferring
Journal: The Impact of Maternal Obesity on the Duration of Labor Stages in Dinoprostone-Induced Vaginal Delivery. (Pubmed Central) - May 14, 2025
However, the duration of the active phase of labor and total induced labor were significantly longer in the obese group. An increased BMI in pregnant women is associated with a longer active phase and overall labor duration during dinoprostone-induced delivery.
- || Cervidil (dinoprostone) / Ferring
Retrospective data, Review, Journal: Topical Dinoprostone vs. Foley's Catheter: A Systematic Review and Meta-Analysis of Cervical Ripening Approaches. (Pubmed Central) - May 14, 2025
In comparison with dinoprostone, Foley's catheter is equally effective and well tolerated. We recommend Foley's catheter use for women with a previous caesarian delivery and in low-resource settings.
- Observational data, Journal, Real-world evidence: Real-World Insights From T (Pubmed Central) - May 13, 2025
We recommend Foley's catheter use for women with a previous caesarian delivery and in low-resource settings. This study offers preliminary evidence supporting the effective and safe use of bDMARDs in patients with SpA and CKD.
- | Firmagon (degarelix) / Astellas, Ferring, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, PARP Biomarker: Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib (Pubmed Central) - May 13, 2025
We observed a shared phenotypic response to combination therapy across prostate cancers without known HR repair gene alterations. This suggests alternative mechanisms rather than antiandrogen-induced HR deficiency.
- | Xtandi (enzalutamide) / Pfizer, Astellas
Trial completion, Trial completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - May 12, 2025
P2, N=19, Completed, Sponsor: University of Colorado, Denver
This suggests alternative mechanisms rather than antiandrogen-induced HR deficiency. Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Jul 2024
- | Eligard (leuprolide acetate) / Tolmar, Sanofi, Firmagon (degarelix) / Astellas, Ferring
Trial completion date: Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study) (clinicaltrials.gov) - May 6, 2025
P=N/A, N=300, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Jul 2024 Trial completion date: Dec 2025 --> Mar 2026
- ||| Rebyota (fecal microbiota, live-jslm) / Ferring
P3 data, Journal: Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA (Pubmed Central) - May 5, 2025
P3
This single-arm study suggests RBL administered via colonoscopy is practical, safe, and effective for preventing CDI recurrence following antibiotic treatment in adults. ClinicalTrials.gov: NCT05831189.
- | Cervidil (dinoprostone) / Ferring
Journal: Uterine hyperstimulation in cervical ripening with oral misoprostol versus dinoprostone vaginal pessary: A real-life single-center descriptive study. (Pubmed Central) - May 3, 2025
ClinicalTrials.gov: NCT05831189. In this group of women, uterine tachysystole and uterine tachysystole with fetal heart rate abnormalities occurred less frequently after cervical ripening with oral misoprostol than after ripening with a dinoprostone pessary.
- |||| Trial completion, Trial completion date: COVER: COVID-19 VaccinE Response in Rheumatology Patients (clinicaltrials.gov) - May 2, 2025
P4, N=841, Completed, Sponsor: Jeffrey Curtis
In this group of women, uterine tachysystole and uterine tachysystole with fetal heart rate abnormalities occurred less frequently after cervical ripening with oral misoprostol than after ripening with a dinoprostone pessary. Recruiting --> Completed | Trial completion date: Sep 2024 --> May 2024
- || Review, Journal: Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer. (Pubmed Central) - Apr 30, 2025
Promising novel therapies, such as immunotherapy, recombinant intravesical therapies, and antibody-drug conjugates are emerging as potential alternatives. These therapies aim to achieve good oncological outcomes while maintaining quality of life, providing an alternative to the decades long standard of care.
- ||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer. (clinicaltrials.gov) - Apr 29, 2025
P2, N=52, Completed, Sponsor: Medical University of South Carolina
These therapies aim to achieve good oncological outcomes while maintaining quality of life, providing an alternative to the decades long standard of care. Active, not recruiting --> Completed
- || Review, Journal: Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis. (Pubmed Central) - Apr 29, 2025
There are many types of drugs to treat psoriasis: small-molecule drugs, including corticosteroids; retinoids; vitamin D analogs; and immunosuppressants, such as glucocorticoid ointment, tretinoin cream, methotrexate tablets, etc. Macromolecular biological drugs, such as Certolizumab, Secukinumab, Guselkumab, etc., include monoclonal antibodies that target various inflammatory signaling pathways...Spesolimab is the latest biological agent used to target the interleukin-36 receptor (IL-36R) to be approved for market use, which significantly reduces the risk of general pustular psoriasis (GPP) flare by 84%...In this review, we analyze the current status of psoriasis therapeutics and discuss novel delivery systems for diverse psoriasis drugs, as well as emerging cell-based therapies. We also summarize the therapeutic effectiveness of different delivery strategies.
- | haloperidol / Generic mfg., pethidine / Samaritan Pharma, Cervidil (dinoprostone) / Ferring
Preclinical, Journal: Association of Labor-Related Medications With Molar Hypomineralization: An Experimental Study in Rats. (Pubmed Central) - Apr 29, 2025
Significant differences (P<0.001) were found in magnesium and phosphorus levels in the group administered pethidine and haloperidol, indicating a significant impact on the mineral composition of teeth. The results suggest that medications administered during delivery could influence dental mineralization, potentially contributing to the development of molar hypomineralization.
- Hernicore (condoliase) / Seikagaku, Ferring
A CLINICAL OVERVIEW OF SI-6603 (CONDOLIASE) FOR RADICULAR LEG PAIN ASSOCIATED WITH LUMBAR DISC HERNIATION (Gatlin C) - Apr 26, 2025 - Abstract #ASRASPRING2025ASRA_SPRING_331;
The results suggest that medications administered during delivery could influence dental mineralization, potentially contributing to the development of molar hypomineralization. Summary of AEs Up to Week 13 in Four RCTs
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial primary completion date: PRIME-CUT: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov) - Apr 25, 2025
P2, N=26, Active, not recruiting, Sponsor: Mark Stein
Summary of AEs Up to Week 13 in Four RCTs N=20 --> 26 | Trial primary completion date: Mar 2024 --> Nov 2026
- || Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Trial completion date, Trial primary completion date: ABLE-22: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Apr 25, 2025
P2, N=150, Recruiting, Sponsor: Ferring Pharmaceuticals
N=20 --> 26 | Trial primary completion date: Mar 2024 --> Nov 2026 Trial completion date: Jul 2028 --> Dec 2030 | Trial primary completion date: Jul 2026 --> Dec 2030
- Intensification of androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC): Patterns of use and impact on outcomes from a large academic medical center. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5734;
Even at a large academic institution, only about half of pts received intensification. Pts not given intensification were older, and patient preference was the most commonly identified reason for not receiving intensification.
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
ABLE-41, a real-world evidence study for bladder cancer patients treated with nadofaragene firadenovec: Baseline patient characteristics and demographics. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5580;
P
Early data from the real-world usage of nadofaragene firadenovec in this study demonstrates patients are older than those in the phase 3 trial but despite having 1 subject with ECOG status > 2, they self-report low levels of pain and limitations on daily living activities. Inclusion of patients outside the FDA label and clinical guidelines may provide unique insights and hypothesis generation.
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non (Hall A - Posters and Exhibits; Poster Bd #: 421b) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1209;
P3
Exploratory endpoints include effect on potential biomarkers and health-related quality of life. Final results are expected in 2031.
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy (Hall A - Posters and Exhibits; Poster Bd #: 420b) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1167;
P2
Final results are expected in 2031. Bladder-preserving treatment options for patients with BCG-unresponsive NMIBC with CIS
- || Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
Review, Journal: Faecal microbiota transplantation for recurrent Clostridiodes difficile infection & its global regulatory landscape. (Pubmed Central) - Apr 21, 2025
The official FMT recommendation for recurrent CDI is emphasised from the perspective of public health, with the argument that early implementation could limit antibiotic overuse and prevent antibiotic resistance. Initiatives like the Universal Stool Bank concept aim to streamline donor selection and distribution procedures to minimise operational restrictions.
- | Journal: Recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease: A scoping review. (Pubmed Central) - Apr 21, 2025
Recommendations for csDMARDs were similar between guidelines. There was significant variability in recommendations for b/tsDMARD use, reflecting current minimal literature in this area.
- | Goofice (elobixibat) / Ipsen
Journal: A novel ultra-sensitive LC-MS/MS method for determination of elobixibat in human plasma; Application to a bioequivalence study on healthy volunteers. (Pubmed Central) - Apr 19, 2025
There was significant variability in recommendations for b/tsDMARD use, reflecting current minimal literature in this area. Full bioanalytical validation as per FDA guidance was done over a range of 20.0-1500.0
- || Hernicore (condoliase) / Seikagaku, Ferring
Clinical data, Journal: Age-specific Comparative Clinical Outcomes of Chemonucleolysis with Condoliase versus Microendoscopic Discectomy in Patients with Lumbar Disc Herniation. (Pubmed Central) - Apr 14, 2025
Condoliase and MED had equivalent 1-year outcomes, with no differences observed in efficacy across age groups. For informed decision-making, the advantages and disadvantages of each treatment must be understood.
- | leuprolide acetate for depot suspension / Generic mfg., Firmagon (degarelix) / Astellas, Ferring
Journal: Therapeutic potential of GNRHR analogs and SRC/FAK inhibitors to counteract tumor growth and metastasis in breast cancer. (Pubmed Central) - Apr 13, 2025
Combining DEGA with PP2 or FAKi enhanced tumor inhibition, improving mice survival. These findings provide valuable insights into the essential regulatory role of gonadotropins in genes involved in tumorigenic processes, highlighting the potential of GnRHR antagonists combined with Src or FAK inhibitors as a promising strategy to develop new drugs that interfere with the ability of breast tumor progression.
- | Cervidil (dinoprostone) / Ferring
Observational data, Journal: Nulliparous Women's Experience in the Immediate Postpartum Period After Cervical Ripening According to the Method: A Prospective Observational Study. (Pubmed Central) - Apr 12, 2025
A prospective observational study included 340 nulliparous women with a singleton fetus in cephalic presentation and cervical ripening at term (?37 weeks) for maternal and/or fetal disease using a cervical ripening balloon (CRB, 33.8%), dinoprostone vaginal insert (PG, 32.7%), oral misoprostol (M, 3.8%), or repeated methods (R, 29.7%)...After adjustment, maternal experience and childbirth were similar between methods used alone for cervical ripening. Nulliparous women who required repeated methods for cervical ripening at term had significantly worse experiences of ripening and childbirth in the immediate postpartum period compared to PG, CRB, or M used alone, regardless of the mode of delivery and maternal and neonatal morbidity.
- Firmagon (degarelix) / Astellas, Ferring
Is the estimated tumor reduction between PSMA PET and final pathology more trustworthy than minimal residual disease in patients undergoing neo-adjuvant ADT? A subanalysis of the randomized phase II ARNEO trial (Marco Polo 701; In Person) - Apr 12, 2025 - Abstract #AUA2025AUA_3821;
The ARNEO trial is a double-blind, placebo-controlled trial, evaluating the role of neoadjuvant degarelix (DEG) with apalutamide (APA) or matching placebo (PLB) before RP in men with high-risk PCa. In this prospective phase II trial, estimated relative reduction between PSMA PET/CT volume and final pathology (defined as ?75% TV decrease) does not seem to be an appropriate surrogate endpoint for BCR-free survival.
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Marco Polo 701; In Person) - Apr 12, 2025 - Abstract #AUA2025AUA_3354;
Rectal diazepam pretreatment reduces bladder spasms and improves nadofaragene retention during intravesical instillation, thereby enhancing patient comfort and medication delivery. Further investigation regarding the impact on treatment efficacy is warranted through larger, prospective studies.
- | Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Journal: Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US. (Pubmed Central) - Apr 11, 2025
Persistence and adherence rates were higher in metastatic prostate cancer. Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: A Case of Rectus Sheath Hematoma Caused by Self-Injection of Certolizumab Pegol. (Pubmed Central) - Apr 8, 2025
This is the first reported case of RSH caused by certolizumab pegol. Factors contributing to RSH include low abdominal wall fat, the use of auto-injector-based preparations, and anticoagulant use in dialysis.
- || Clinical, Review, Journal: Gonadotropins for ovulation induction in women with polycystic ovary syndrome. (Pubmed Central) - Apr 7, 2025
We are uncertain if gonadotropins reduce ectopic pregnancy. None of the women developed OHSS.
- | Cervidil (dinoprostone) / Ferring
Retrospective data, Journal: Comparison of the efficacy and safety of dinoprostone and double-balloon catheters in cervical ripening: a propensity score matching retrospective study. (Pubmed Central) - Apr 7, 2025
None of the women developed OHSS. Dinoprostone is associated with a lower puerperal infection rate and improved Bishop score in IOL without an increased success rate of vaginal delivery.